PMS-METOCLOPRAMIDE TABLETS 5 MG
METOCLOPRAMIDE HYDROCHLORIDE : 5 MG · DIN 02230431 · PHARMASCIENCE INC
Health Canada status: MARKETED
What is PMS-METOCLOPRAMIDE TABLETS?
PMS-METOCLOPRAMIDE TABLETS 5 MG contains METOCLOPRAMIDE HYDROCHLORIDE : 5 MG. It is listed in the Health Canada Drug Product Database under DIN 02230431, held by PHARMASCIENCE INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 29-Oct-2021. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is PMS-METOCLOPRAMIDE TABLETS used for?
As an adjunct in the management of delayed gastric emptying associated with subacute and chronic gastritis or following vagotomy, pyloroplasty and other surgical procedures. As an adjunct to facilitate small bowel intubation and gastroduodenal evacuation of barium meals. To reduce postoperative vomiting induced by narcotics when used pre-operatively by the oral route.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
What else is PMS-METOCLOPRAMIDE TABLETS called?
The same molecule, METOCLOPRAMIDE, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| PRIMPERAN | Latin | Morocco |
| CLOPRAME | Latin | Morocco |
| Metoclopramide HCl Medsurge | Latin | Australia |
| METOCLOPRAMIDE INJECTION BP | Latin | Australia |
| APO-Metoclopramide | Latin | Australia |
| EMEXLON | Latin | Australia |
| Maxolon | Latin | Australia |
| METOCLOPRAMIDE-WGR | Latin | Australia |
| Pramin | Latin | Australia |
| Setin | Latin | South Africa |
| Maxolon t | Latin | South Africa |
| METAGLIZ | Latin | Morocco |
| PRAMIDOL | Latin | Morocco |
| Betaclopramide | Latin | South Africa |
| Clopamon-S | Latin | South Africa |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
Product details and regulatory record
| DIN | 02230431 |
|---|---|
| Brand name | PMS-METOCLOPRAMIDE TABLETS |
| Generic / active ingredient | METOCLOPRAMIDE HYDROCHLORIDE : 5 MG |
| Manufacturer | PHARMASCIENCE INC |
| Strength | 5 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | A03FA01 METOCLOPRAMIDE |
| AHFS class | 88:28.01* ; See footnote |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 29-Oct-2021 |
| Original market date | 1997-03-26 00:00:00 |
How is this product identified?
Purchase orders, customs paperwork and tender documents each ask for a different identifier, and a DIN written without its leading zeros is the single most common reason an order line fails to match. Every form Nexara accepts for this product is listed here.
| DIN (8-digit, as used in Nexara ordering) | 02230431 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2230431 |
| Brand name | PMS-METOCLOPRAMIDE TABLETS |
| Active ingredient / INN | METOCLOPRAMIDE HYDROCHLORIDE : 5 MG |
| ATC code | A03FA01 |
| ATC anatomical main group | A — Alimentary tract and metabolism |
| ATC therapeutic subgroup | A03 |
| AHFS class | 88:28.01* ; See footnote |
| Health Canada schedule | Prescription |
| Biosimilar biologic | No |
| Market authorization holder | PHARMASCIENCE INC |
How is it administered?
Adults: 5-10 mg 3-4 times daily before meals. Max daily dose 0.5 mg/kg. Duration should not exceed 12 weeks. Reduced dose for elderly, renal/hepatic impairment.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
null
How is it supplied?
Tablets: HDPE bottles of 100 tablets (5 mg and 10 mg). Oral Solution: HDPE bottles of 500 mL.
Which pack is which?
| Strength on the label | 5 MG |
|---|---|
| Dosage form | TABLET |
| Route | ORAL |
| Packaging as described in the monograph | Tablets: HDPE bottles of 100 tablets (5 mg and 10 mg). Oral Solution: HDPE bottles of 500 mL. |
| Storage | null |
One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced. Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Contraindications
Hypersensitivity; history of tardive dyskinesia or dystonic reaction; GI hemorrhage, obstruction, or perforation; pheochromocytoma; epilepsy; concomitant drugs causing extrapyramidal reactions.
Warnings and precautions
Tardive dyskinesia (often irreversible, risk increases with duration); Extrapyramidal symptoms; Neuroleptic Malignant Syndrome; Depression/suicidality; Hypertension; Fluid retention.
What can be used instead?
Other Canadian products sharing ATC code A03FA01 METOCLOPRAMIDE. 10 of 34 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| MAR-METOCLOPRAMIDE | 5 MG | TABLET | MARCAN PHARMACEUTICALS INC | MARKETED | DIN 02517795 |
| METOCLOPRAMIDE HYDROCHLORIDE INJECTION | 5 MG | SOLUTION | JAMP PHARMA CORPORATION | MARKETED | DIN 02537397 |
| METOCLOPRAMIDE HYDROCHLORIDE INJECTION | 5 MG | SOLUTION | BAXTER CORPORATION | MARKETED | DIN 02531747 |
| METOCLOPRAMIDE HYDROCHLORIDE INJECTION | Strength | Liquid | SANDOZ CANADA INCORPORATED 4600 Rue Armand-Frappier Saint-Hubert Quebec Canada J3Z 1G5 | MARKETED | DIN 02185431 |
| METOCLOPRAMIDE INJECTION USP | 5 MG | SOLUTION | OMEGA LABORATORIES LIMITED | MARKETED | DIN 02243563 |
| PMS-METOCLOPRAMIDE HYDROCHLORIDE INJECTION | 5 MG | SOLUTION | PHARMASCIENCE INC | MARKETED | DIN 02510790 |
| PMS-METOCLOPRAMIDE ORAL SOLUTION | 5 MG / 5 ML | SOLUTION | PHARMASCIENCE INC | MARKETED | DIN 02230433 |
| PRZ-METOCLOPRAMIDE | 10 MG | TABLET | PHARMARIS CANADA INC | MARKETED | DIN 02548755 |
| PRZ-METOCLOPRAMIDE | 5 MG | TABLET | PHARMARIS CANADA INC | MARKETED | DIN 02548747 |
| APO-METOCLOP TAB 10MG | 10 MG | TABLET | APOTEX INC | DORMANT | DIN 00842834 |
Who else supplies METOCLOPRAMIDE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. METOCLOPRAMIDE appears in 159 registered pack listings across 11 markets, published on 9 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How much does METOCLOPRAMIDE cost around the world?
METOCLOPRAMIDE is listed on 8 national price registers Nexara tracks, across 114 pack listings published on 8 different price bases. What each country publishes is set out below.
| Market | What that country publishes | Brands listed | Pack listings | As of |
|---|---|---|---|---|
| United States | acquisition | 4 | 35 | 03 Sep 2026 |
| Morocco | PPV (public price) | 8 | 26 | 05 Sep 2026 |
| Australia | ex-manufacturer | 7 | 23 | 08 Sep 2026 |
| South Africa | single exit price | 12 | 17 | 01 Sep 2026 |
| Greece | producer price (ex-factory) | 6 | 6 | 03 Sep 2026 |
| United Kingdom | hospital | 4 | 4 | 31 Aug 2026 |
| Italy | prezzo al pubblico (classe A) | 2 | 2 | 02 Sep 2026 |
| Lebanon | public price (USD, Decision 119/1) | 1 | 1 | 02 Sep 2026 |
Why there are no figures here. These bases are not comparable. A Brazilian ex-factory ceiling, a Belgian pharmacy public price and a Japanese reimbursement rate answer three different questions, and none of them is what a product lands in Canada for. Putting them side by side would mislead in both directions, so Nexara publishes where a molecule is listed and on what basis, and quotes the delivered Canadian price per order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.